002370 Zhejiang Yatai Pharmaceutical
- 3.31
- -0.12-3.50%
Zhejiang Yatai Pharmaceutical News
Asia Pacific Pharmaceutical: Report for the third quarter of 2024
zhejiang yatai pharmaceutical (002370.SZ): a net loss of 3.4595 million yuan in the first three quarters.
Gelonghui On October 30th, Zhejiang Yatai Pharmaceutical (002370.SZ) released its third-quarter report for 2024, achieving revenue of 0.307 billion yuan in the first three quarters, a year-on-year increase of 1.65%; net income attributable to the shareholders of the listed company was -3.4595 million yuan; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was -22.5921 million yuan; basic earnings per share was -0.0056 yuan.
Zhejiang Yatai Pharmaceutical (002370.SZ): Plans to sell 100% equity and debt forgiveness of Shanghai Xingaofeng.
On September 9th, GeLonghui reported that Zhejiang Yatai Pharmaceutical (002370.SZ) announced that at the 31st meeting of the seventh board of directors held on September 9th, 2024, it passed the "Proposal on the sale of 100% equity and debt exemption of wholly-owned subsidiary". On September 9th, 2024, the company signed the "Equity Transfer Agreement of Shanghai Xingaofeng Biomedical Co., Ltd." with Ningbo Heyi Culture Media Co., Ltd. (referred to as "Heyi Culture"), transferring 100% equity of Shanghai Xingaofeng Biomedical Co., Ltd. (referred to as "Shanghai Xingaofeng") held by the company to Heyi Culture. Due to Shanghai.
Zhejiang Yatai Pharmaceutical (002370.SZ): Received the acceptance notice of the consistency evaluation of Atorvastatin tablets.
Galion reported on September 6th that zhejiang yatai pharmaceutical (002370.SZ) announced that the company recently received the acceptance notice of the consistency evaluation of Atorvastatin tablets issued by the National Medical Products Administration. Atorvastatin tablets are mainly used to treat hypertension, angina, myocardial infarction, and can also be used for arrhythmia, hyperthyroidism, and pheochromocytoma.
There is a risk of diffusion! WHO has launched a global strategic preparedness, and monkeypox concept stocks have surged in response.
New variant appears.
Zhejiang Yatai Pharmaceutical: Half-year report for the year 2024.
Zhejiang Yatai Pharmaceutical: Summary of Half-Year Report in 2024.
Zhejiang Yatai Pharmaceutical (002370.SZ) released its performance for the first half of the year, with a net income of 5.4752 million yuan, a 72.30% decrease.
zhejiang yatai pharmaceutical (002370.SZ) released the 2024 interim report, during the reporting period, the company achieved revenue...
Zhejiang Yatai Pharmaceutical (002370.SZ): The net income in the first half of the year was 54.752 million yuan, a 72.30% decrease year-on-year.
Gelonghui August 23rd, Zhejiang Yatai Pharmaceutical (002370.SZ) released the 2024 interim report, with revenue of 0.222 billion yuan during the reporting period, a 0.36% year-on-year increase; net income attributable to shareholders of the listed company was 5.4752 million yuan, a 72.30% year-on-year decrease; net income attributable to shareholders of the listed company excluding non-recurring gains and losses was -7.8267 million yuan; basic earnings per share was 0.01 yuan.
Zhejiang Yatai Pharmaceutical (002370.SZ): The specification of Cefpodoxime proxetil for injection has been increased and passed the consistency evaluation of generic drugs.
Zhejiang Yatai Pharmaceutical (002370.SZ) has announced that the company recently received approval and issuance from the National Medical Products Administration...
Optimistic Investors Push Zhejiang Yatai Pharmaceutical Co., Ltd. (SZSE:002370) Shares Up 29% But Growth Is Lacking
Zhejiang Yatai Pharmaceutical (002370.SZ): The controlling shareholder Fubon Group has completed the shareholding of 2.01%.
Zhejiang Yatai Pharmaceutical (002370.SZ) announced that up to the disclosure date of this announcement, the controlling shareholder of the company, Fubon Group, has accumulated an additional 12.27 million shares of the company through the Shenzhen Stock Exchange's centralized bidding trading system, with a total additional investment of 36,364,912.15 yuan, accounting for 2.01% of the total share capital of the company. The shareholding plan has been fully implemented upon completion.
Zhejiang Yatai Pharmaceutical: 2024 Interim Performance Forecast
Zhejiang Yatai Pharmaceutical (002370.SZ): Net income is expected to decrease by 67.12%-77.23% in the first half of the year.
Zhejiang Yatai pharmaceutical (002370.SZ) announced its performance forecast for the first half of 2024. The net income attributable to the shareholders of the listed company during the reporting period is expected to be between 4.5 million and 6.5 million yuan, a decrease of 67.12% - 77.23% compared to the same period last year; the net income after deducting non-recurring gains and losses is expected to be a loss of 6.8 million to 8.8 million yuan, a decrease of 73.99% - 79.90% compared to the same period last year; the revenue is expected to be 220 million to 230 million yuan; the basic earnings per share is expected to be between 0.0074 yuan/share and 0.0107 yuan/share. The company's net income attributable to shareholders of the listed company for the current period.
The controlling shareholder of Asia Pacific Pharmaceutical (002370.SZ) increased its cumulative shareholding by 2.01%
Asia Pacific Pharmaceutical (002370.SZ) issued an announcement. The company received Ning, the controlling shareholder of the company, on May 6, 2024...
Asia Pacific Pharmaceutical (002370.SZ): Net loss of 2.9984 million yuan in the first quarter
Gelonghui, April 26 | Asia Pacific Pharmaceutical (002370.SZ) released its report for the first quarter of 2024. Operating income for the reporting period was 113 million yuan, down 8.80% from the previous year; net profit attributable to shareholders of listed companies - RMB 29.984 million; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - RMB 2,211,300; and basic earnings per share - 0.0049 yuan.
Asia Pacific Pharmaceutical (002370.SZ) reported 2023 annual results, with a net loss of 11.877 million yuan, which narrowed the year-on-year loss
Asia Pacific Pharmaceutical (002370.SZ) released its 2023 annual report. The company achieved operating income of 4 during the reporting period...
Asia Pacific Pharmaceutical (002370.SZ): 3 products collected in the country (injectable omeprazole sodium, injectable cefumezole sodium, cefixime capsules)
Gelonghui, Feb. 29 | Asia Pacific Pharmaceutical (002370.SZ) said on the investor interactive platform that the company has entered the national collection of 3 products (injectable omeprazole sodium, injectable cefamezole sodium, cefixime capsules).
Asia Pacific Pharmaceutical (002370.SZ): No drugs to treat nuclear contamination
Gelonghui, Feb. 21丨An investor asked Asia Pacific Pharmaceutical (002370.SZ) on the investor interactive platform, “Are your company's drugs aimed at treating nuclear pollution?” The company replied that the company has no drugs to treat nuclear contamination.
Fubon Group, the controlling shareholder of Asia Pacific Pharmaceutical (002370.SZ), increased 1.67% of the company's shares
According to Zhitong Finance App, Asia Pacific Pharmaceutical (002370.SZ) issued an announcement. On February 7, 2024, the company received a notice from the controlling shareholder Fubon Group. From February 6, 2024 to February 7, 2024, Fubon Group increased its holdings of the company's shares by 10.17 million shares through centralized bidding transactions through the Shenzhen Stock Exchange system, accounting for 1.67% of the company's total share capital.
Analysis
Price Target
No Data
No Data